SG163585A1 - Melanocortin receptor ligands - Google Patents

Melanocortin receptor ligands

Info

Publication number
SG163585A1
SG163585A1 SG201004921-1A SG2010049211A SG163585A1 SG 163585 A1 SG163585 A1 SG 163585A1 SG 2010049211 A SG2010049211 A SG 2010049211A SG 163585 A1 SG163585 A1 SG 163585A1
Authority
SG
Singapore
Prior art keywords
receptor ligands
melanocortin receptor
compounds
ligands
pharmaceutically
Prior art date
Application number
SG201004921-1A
Other languages
English (en)
Inventor
Dong Zheng Xin
Jacques-Pierre Moreau
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of SG163585A1 publication Critical patent/SG163585A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
SG201004921-1A 2005-07-08 2006-07-10 Melanocortin receptor ligands SG163585A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69777905P 2005-07-08 2005-07-08
US74885005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
SG163585A1 true SG163585A1 (en) 2010-08-30

Family

ID=37637790

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201004921-1A SG163585A1 (en) 2005-07-08 2006-07-10 Melanocortin receptor ligands

Country Status (21)

Country Link
US (8) US8039435B2 (fr)
EP (6) EP2286825B1 (fr)
JP (4) JP4734411B2 (fr)
KR (2) KR101232201B1 (fr)
CN (4) CN101676298A (fr)
AU (2) AU2006269261B2 (fr)
CA (4) CA3228910A1 (fr)
DK (4) DK2548568T3 (fr)
ES (4) ES2877349T3 (fr)
FR (1) FR21C1060I2 (fr)
HK (2) HK1149190A1 (fr)
HU (4) HUE037147T2 (fr)
IL (3) IL188545A (fr)
NL (1) NL301150I2 (fr)
NZ (2) NZ580806A (fr)
PL (4) PL2286825T3 (fr)
PT (4) PT2236151E (fr)
RU (2) RU2380372C2 (fr)
SG (1) SG163585A1 (fr)
SI (1) SI3354273T1 (fr)
WO (1) WO2007008704A2 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2877349T3 (es) * 2005-07-08 2021-11-16 Ipsen Pharma Ligandos de los receptores de la melanocortina
DE102007020152A1 (de) * 2007-04-26 2008-10-30 Charité - Universitätsmedizin Berlin Mittel zur antiinfektiven Behandlung eines Patienten
RU2450017C2 (ru) * 2007-05-25 2012-05-10 Ипсен Фарма С.А.С. Лиганды меланокортиновых рецепторов, модифицированные гидантоином
AR066175A1 (es) * 2007-06-15 2009-08-05 Sod Conseils Rech Applic Ligandos del receptor de melanocortina de peptidos ciclicos
PL2214693T3 (pl) * 2007-11-05 2016-03-31 Ipsen Pharma Sas Zastosowanie melanokortyn do leczenia insulinowrażliwości
PT2816055T (pt) 2008-05-27 2019-03-18 Genzyme Corp Análogos peptídicos de hormonas estimulantes de alfa-melanócitos
EA018630B1 (ru) 2008-06-09 2013-09-30 Палатин Текнолоджиз, Инк. Специфичные к меланокортиновым рецепторам пептиды для лечения сексуальной дисфункции
EA020959B1 (ru) 2009-06-08 2015-03-31 Палатин Текнолоджиз, Инк. Пептиды, специфичные к меланокортиновым рецепторам
WO2010144341A2 (fr) 2009-06-08 2010-12-16 Palatin Technologies, Inc. Peptides spécifiques des récepteurs aux mélanocortines à pont lactame
UY32690A (es) 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
CA2769883A1 (fr) * 2009-08-05 2011-02-10 Ipsen Pharma S.A.S. Utilisation de melanocortines pour traiter la dyslipidemie
US8541545B2 (en) * 2009-08-31 2013-09-24 Tensive Controls Inc. Stabilized melanocortin ligands
WO2011060352A1 (fr) * 2009-11-16 2011-05-19 Ipsen Pharma S.A.S. Compositions pharmaceutiques de ligands de recepteurs de la melanocortine
RU2012125033A (ru) * 2009-11-16 2014-01-20 Ипсен Фарма С.А.С. СПОСОБ СИНТЕЗА Ас-Arg-ЦИКЛО(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
BR112012011787B1 (pt) 2009-11-23 2022-03-03 Palatin Technologies, Inc Peptídeo cíclico e composição farmacêutica
JP2013511554A (ja) 2009-11-23 2013-04-04 パラティン テクノロジーズ，インコーポレイテッド メラノコルチン−１受容体特異的線状ペプチド
MX341642B (es) * 2011-06-14 2016-08-29 Ipsen Pharma Sas Composicion de liberacion sostenida que contiene peptidos como ingredientes activos.
HRP20211950T1 (hr) 2011-12-29 2022-03-18 Rhythm Pharmaceuticals, Inc. Postupak liječenja poremećaja u vezi sa melanokortin-4 receptorom u heterozigotnim nosiocima
EP2705835A1 (fr) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2668791C2 (ru) 2012-10-19 2018-10-02 ТиЭксПи ФАРМА ГМБХ АНАЛОГИ АЛЬФА- и ГАММА-MSH
EP2968475A2 (fr) 2013-03-14 2016-01-20 Questcor Pharmaceuticals, Inc. Acth dans le traitement du syndrome de détresse respiratoire aiguë
PL2970389T3 (pl) * 2013-03-15 2021-03-08 Rhythm Pharmaceuticals, Inc. Kompozycje farmaceutyczne
CN105492456A (zh) * 2013-03-15 2016-04-13 节奏制药公司 肽组合物
AU2015249540B2 (en) 2014-04-22 2019-08-22 Txp Pharma Gmbh Peptide analogues with branched amino acid probe(s)
KR20180063221A (ko) 2015-09-30 2018-06-11 리듬 파마슈티컬즈, 인코포레이티드 멜라노코르틴-4 수용체 경로-관련 장애의 치료 방법
WO2017066754A1 (fr) * 2015-10-15 2017-04-20 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions et méthodes de traitement de la dépression et de l'anxiété
US11542302B2 (en) 2015-10-15 2023-01-03 Arizona Board Of Regents On Behalf Of The University Of Arizona Modulators of melanocortin receptors for the treatment of depression and anxiety
US20190255142A1 (en) * 2016-10-17 2019-08-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Novel modulators of melanocortin receptors for the treatment of depression and anxiety
JP2020514365A (ja) * 2017-03-15 2020-05-21 ノヴォ ノルディスク アー／エス メラノコルチン４受容体に結合可能な二環式化合物
US20210169969A1 (en) 2018-04-06 2021-06-10 Leonardus H.T. Van Der Ploeg Compositions for treating kidney disease
WO2019219714A1 (fr) * 2018-05-15 2019-11-21 Novo Nordisk A/S Composés capables de se lier au récepteur de la mélanocortine 4
CN113260625A (zh) * 2018-05-23 2021-08-13 省卫生服务机构 用于成像或治疗的放射性标记的黑皮质素1受体特异性α-黑素细胞刺激激素类似物
US11396535B2 (en) 2019-03-01 2022-07-26 Provincial Health Services Authority Cyclic peptide analogs of melanocortin and amanitin and methods of making such
EP4216979A1 (fr) * 2020-09-24 2023-08-02 Rhythm Pharmaceuticals, Inc. Méthodes de traitement de troubles associés à la voie d'un récepteur de la mélanocortine-4
WO2022251650A1 (fr) * 2021-05-27 2022-12-01 The Regents Of The University Of Michigan Peptides agonistes du mc3r
WO2024083843A1 (fr) 2022-10-18 2024-04-25 Confo Therapeutics N.V. Séquences d'acides aminés dirigées contre le récepteur de la mélanocortine 4 et polypeptides les comprenant pour le traitement de maladies et de troubles liés à mc4r

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US613874A (en) 1898-11-08 George e
US1613874A (en) 1922-03-29 1927-01-11 Miner Inc W H Friction draft gear
US5652214A (en) 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US5672659A (en) 1993-01-06 1997-09-30 Kinerton Limited Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides
US5595760A (en) 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5665702A (en) 1995-06-06 1997-09-09 Biomeasure Incorporated Ionic molecular conjugates of N-acylated derivatives of poly(2-amino-2-deoxy-D-glucose) and polypeptides
US5916883A (en) 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
SE9700620D0 (sv) 1997-02-21 1997-02-21 Wapharm Ab Cykliska peptider med selektivitet för MSH-receptor subtyper
US6350430B1 (en) 1997-10-27 2002-02-26 Lion Bioscience Science Ag Melanocortin receptor ligands and methods of using same
EP1076649A4 (fr) 1998-04-28 2010-06-02 Trega Biosciences Inc Composes a base d'isoquinoline tenant lieu de ligands de recepteurs de melanocortine et procedes d'utilisation
HUP0102715A3 (en) * 1998-07-27 2004-10-28 Univ Iowa State Res Found Inc Melanocortin-4 receptor gene and use as a genetic marker for fat content, weight gain, and/or feed consumption of animals
WO2000010507A2 (fr) 1998-08-21 2000-03-02 The Children's Medical Center Corporation Utilisation de melanine pour inhiber l'angiogenese et la degenerescence maculaire
US6603058B1 (en) 1998-12-09 2003-08-05 Oklahoma Medical Research Foundation Non-human animal model for obesity and uses thereof
US6716810B1 (en) 1998-12-09 2004-04-06 Eleanor Roosevelt Institute Composition and method for regulation of body weight and associated conditions
ID30262A (id) 1999-03-29 2001-11-15 Procter & Gamble Ligan reseptor melanokortin
US6579968B1 (en) * 1999-06-29 2003-06-17 Palatin Technologies, Inc. Compositions and methods for treatment of sexual dysfunction
US7176279B2 (en) 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
JP2003513645A (ja) 1999-11-12 2003-04-15 メルク エンド カムパニー インコーポレーテッド メラノコルチン−３レセプター欠失細胞、非ヒトトランスジェニック動物及び体重を調節する化合物の選択方法
US6600015B2 (en) 2000-04-04 2003-07-29 Hoffmann-La Roche Inc. Selective linear peptides with melanocortin-4 receptor (MC4-R) agonist activity
KR20030017571A (ko) * 2000-06-28 2003-03-03 화이자 프로덕츠 인크. 멜라노코르틴 수용체 리간드
US6720324B2 (en) 2000-07-05 2004-04-13 Synaptic Pharmaceutical Corporation Selective melanin concentrating hormone-1 (MCH1) receptor antagonists and uses thereof
CA2422068A1 (fr) 2000-09-13 2002-03-21 Eleanor Roosevelt Institute Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
US20030113263A1 (en) 2001-02-13 2003-06-19 Oregon Health And Sciences University, A Non-Profit Organization Methods and reagents for using mammalian melanocortin receptor antagonists to treat cachexia
CA2438272A1 (fr) 2001-03-02 2002-10-10 John Macor Composes utiles comme modulateurs des recepteurs de la melanocortine et compositions pharmaceutiques renfermant ceux-ci
US6770645B2 (en) * 2001-03-16 2004-08-03 Pfizer Inc. Pharmaceutically active compounds
CA2453515A1 (fr) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Peptides lineaires et cycliques specifiques du recepteur de melanocortine
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
US20040128136A1 (en) * 2002-09-20 2004-07-01 Irani Pourang Polad Internet voice browser
JP2006527773A (ja) * 2003-06-19 2006-12-07 イーライ リリー アンド カンパニー メラノコルチン受容体４（ｍｃ４）作用薬とその用途
EP1644022A1 (fr) 2003-06-19 2006-04-12 Eli Lilly And Company Utilisation de peptides agonistes du recepteur de la melanocortine-3 (mc3r)
US7084111B2 (en) 2003-06-23 2006-08-01 University Of Florida Research Foundation, Inc. Melanocortin receptor templates, peptides, and use thereof
MXPA06001916A (es) 2003-08-20 2006-05-17 Lilly Co Eli Compuestos, metodos y formulaciones para el suministro oral de un compuesto peptidico similar a glucagona (glp)-i o un peptido agonista del receptor de melanocortina 4 (mc4).
ATE350369T1 (de) * 2003-08-20 2007-01-15 Lilly Co Eli Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagon like peptide (glp)-1-verbindung oder eines am melanocortin-4- rezeptor (mc4) als agonist wirkenden peptids
WO2005040109A1 (fr) * 2003-10-22 2005-05-06 Neurocrine Biosciences, Inc. Ligands du recepteur de la melanocortine et compositions et methodes associees
DE10355559A1 (de) 2003-11-21 2005-06-23 Orthogen Ag Transskin
EP1694348A4 (fr) 2003-12-10 2009-07-01 Merck & Co Inc Inhibition volontaire de consommation d'ethanol au moyen d'agonistes du recepteur 4 de la melanocortine
EP1732586A1 (fr) 2004-03-29 2006-12-20 Eli Lilly And Company Utilisations de peptides agonistes du recepteur de la melanocortine 4 (mc4r) administres par perfusion continue
EP2368562B1 (fr) 2004-10-08 2015-06-17 Clinuvel Pharmaceuticals Limited Compositions et procédés pour induire la mélanogenèse chez un sujet
WO2006073771A2 (fr) 2005-01-05 2006-07-13 Eli Lilly And Company Peptides d'agonistes mc4r ou mc3r lies au polyethyleneglycol
WO2006073772A1 (fr) 2005-01-05 2006-07-13 Eli Lilly And Company Peptides agonistes de mc4r ou de mc3r lies a un polyethyleneglycol
ES2877349T3 (es) * 2005-07-08 2021-11-16 Ipsen Pharma Ligandos de los receptores de la melanocortina
NZ566489A (en) 2005-08-26 2008-10-31 Action Pharma As Therapeutically active alpha-MSH analogues

Also Published As

Publication number Publication date
CN105837661B (zh) 2024-10-15
EP2286825A3 (fr) 2011-07-27
JP2009500427A (ja) 2009-01-08
DK2548568T3 (en) 2018-03-12
IL201732A0 (en) 2010-06-16
EP2548568A3 (fr) 2013-07-17
US20110183886A1 (en) 2011-07-28
RU2380372C2 (ru) 2010-01-27
PL3354273T3 (pl) 2021-10-11
EP2236151A1 (fr) 2010-10-06
AU2006269261A1 (en) 2007-01-18
US20220127305A1 (en) 2022-04-28
CA2793119C (fr) 2019-07-23
PT2286825T (pt) 2017-01-02
US20180105557A1 (en) 2018-04-19
US9458195B2 (en) 2016-10-04
EP2548568B1 (fr) 2018-01-10
IL201732A (en) 2016-07-31
US20200095281A1 (en) 2020-03-26
NZ565217A (en) 2010-03-26
EP2286825A2 (fr) 2011-02-23
CN101257916B (zh) 2013-04-03
HUE037147T2 (hu) 2018-08-28
US20170240595A1 (en) 2017-08-24
CA3228910A1 (fr) 2007-01-18
PT3354273T (pt) 2021-06-28
CA2614615A1 (fr) 2007-01-18
HUE055154T2 (hu) 2021-11-29
JP5889513B2 (ja) 2016-03-22
CN103755786A (zh) 2014-04-30
EP1915167A2 (fr) 2008-04-30
CA2614615C (fr) 2012-10-16
AU2009230799A1 (en) 2009-11-19
SI3354273T1 (sl) 2021-10-29
RU2439079C2 (ru) 2012-01-10
CN103755786B (zh) 2016-05-11
EP2236151B1 (fr) 2012-05-23
RU2009131092A (ru) 2011-02-20
CN105837661A (zh) 2016-08-10
US8039435B2 (en) 2011-10-18
HUS2100054I1 (hu) 2021-12-28
NL301150I2 (nl) 2022-11-24
EP3354273A1 (fr) 2018-08-01
EP2286825B1 (fr) 2016-09-28
NL301150I1 (fr) 2021-12-08
JP2015232003A (ja) 2015-12-24
CN101257916A (zh) 2008-09-03
WO2007008704A2 (fr) 2007-01-18
DK2236151T3 (da) 2012-07-09
PL2548568T3 (pl) 2018-06-29
PT2236151E (pt) 2012-07-02
WO2007008704A3 (fr) 2007-10-11
DK3354273T3 (da) 2021-06-28
EP3354273B1 (fr) 2021-03-24
PL2286825T3 (pl) 2017-06-30
EP3925614A2 (fr) 2021-12-22
CA3044795A1 (fr) 2007-01-18
ES2663916T3 (es) 2018-04-17
US20160368962A1 (en) 2016-12-22
IL188545A0 (en) 2008-04-13
EP2548568A2 (fr) 2013-01-23
HUE031731T2 (en) 2017-07-28
EP1915167A4 (fr) 2010-04-07
CA2793119A1 (fr) 2007-01-18
KR100997177B1 (ko) 2010-11-29
FR21C1060I2 (fr) 2022-12-02
JP4734411B2 (ja) 2011-07-27
ES2877349T3 (es) 2021-11-16
US20180305406A1 (en) 2018-10-25
ES2604328T3 (es) 2017-03-06
CN101676298A (zh) 2010-03-24
NZ580806A (en) 2012-07-27
DK2286825T3 (en) 2017-01-09
ES2386862T3 (es) 2012-09-03
FR21C1060I1 (fr) 2022-01-21
PL2236151T3 (pl) 2012-10-31
RU2008104803A (ru) 2009-08-20
US20100279922A1 (en) 2010-11-04
IL188545A (en) 2011-08-31
JP2013253090A (ja) 2013-12-19
AU2009230799B2 (en) 2012-02-09
HK1149190A1 (en) 2011-09-30
KR20100016120A (ko) 2010-02-12
JP2010090130A (ja) 2010-04-22
AU2006269261B2 (en) 2009-12-17
HK1258965A1 (zh) 2019-11-22
KR101232201B1 (ko) 2013-02-12
KR20080049711A (ko) 2008-06-04
US9850280B2 (en) 2017-12-26
JP5965520B2 (ja) 2016-08-03
PT2548568T (pt) 2018-03-21
IL246392A (en) 2017-07-31
EP3925614A3 (fr) 2022-03-23

Similar Documents

Publication Publication Date Title
SG163585A1 (en) Melanocortin receptor ligands
WO2007008684A3 (fr) Ligands de recepteurs de melanocortine
MY148634A (en) Pyridazinone derivatives
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
TW200740814A (en) Compounds
ATE469895T1 (de) Cgrp-rezeptorantagonisten
MX2009007077A (es) Analogos de ciclopamina.
WO2008156677A3 (fr) Ligands peptidiques cycliques des récepteurs de la mélanocortine
MX2009009540A (es) Inhibidores de metaloproteasa que contienen una porcion heterociclica.
EP1861399A4 (fr) Antagonistes du recepteur du cgrp
EA200700365A1 (ru) Производные индол-2-карбоксамидина как антагонисты nmda рецептора
IL182317A0 (en) Cgrp receptor antagonists
MX2009007104A (es) Derivados de oxindol sustituido y su uso como ligandos del receptor de vasopresina.
PT1877364E (pt) Derivados fenilacetileno com afinidade para o receptor mglur5
MX2010008375A (es) Derivados de piperidina espirocíclicos substituidos como ligandos de receptores de histamina-3 (h3).
EP1802372A4 (fr) Antagonistes des recepteurs du cgrp)
GEP20135959B (en) Aryl piperazine and their usage as alpha2c antagonists
ZA200801875B (en) Isoquinolines as IGF-IR inhibitors
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
SG158091A1 (en) Imidazoazepinone compounds
MX2009008028A (es) Agentes antiparasitarios.
MXPA05013149A (es) Derivados de imidazol como antagonistas del receptor de glutamato.
EA200801549A1 (ru) Новые производные фенантридина в качестве антагонистов брадикинина
TW200613317A (en) Steroid prodrugs with androgenic action
UA106200C2 (uk) Заміщені похідні оксіндолу та їхнє застосування для лікування захворювань, залежних від вазопресину